What is Hepion Pharmaceuticals, Inc. (HEPA) stock price today?

Hepion Pharmaceuticals, Inc. (HEPA) is currently trading at $0.05, up 17.78% today.

What is HEPA P/E ratio?

Hepion Pharmaceuticals, Inc.'s P/E ratio is -0.21. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is HEPA return on equity (ROE)?

Hepion Pharmaceuticals, Inc.'s return on equity (ROE) is -102.45%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Hepion Pharmaceuticals, Inc.'s market cap?

Hepion Pharmaceuticals, Inc. has a market capitalization of $617116.

OTC · Biotechnology

Hepion Pharmaceuticals, Inc. (HEPA) Stock

$0.05 +17.78% OTC: HEPA Healthcare

Valuation

Metric	Value
Price	$0.05
Market Cap	$617116
P/E Ratio	-0.21
P/B Ratio	0.33
P/S Ratio	0.00
EPS (TTM)	$-0.88
52-Week High	$0.11
52-Week Low	$0.03
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-102.45%
ROA	-110.25%
ROCE	-186.89%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.00
Current Ratio	3.68

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-30.0M	$-45.0M	$-48.0M	$-19.0M	$-4.0M
Net Profit	$-33.0M	$-42.0M	$-49.0M	$-13.0M	$-8.0M
EPS	$-465.52	$-594.75	$-616.07	$-107.35	$-0.88
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$104.0M	$60.0M	$18.0M	$2.0M	$3.0M
Total Liabilities	$11.0M	$10.0M	$11.0M	$3.0M	$0
Cash	$91.0M	$51.0M	$15.0M	$0	$2.0M
Borrowings	$0	$0	$0	$3.0M	$0

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-31.0M	$-35.0M	$-41.0M	$-18.0M	$-3.0M
Investing Cash Flow	$0	$0	$0	$-1.0M	$0
Financing Cash Flow	$0	$-2.0M	$4.0M	$2.0M	$-1.0M
Net Cash Flow	$51.0M	$-40.0M	$-36.0M	$-14.0M	$1.0M
Free Cash Flow	$-31.0M	$-35.0M	$-41.0M	$-18.0M	$-3.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	0.67
FCF Yield	-255.30%
Quick Ratio	3.68
Interest Coverage	-161.32
Return 1Y	6.00%
Return 3Y	-99.99%
Return 5Y	-100.00%

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
CDT	$3.14	+9.60%	0.00	$1.53M	0.00%
COCH	$0.67	+1.71%	-0.74	$14.02M	0.00%
ENVB	$1.34	+3.88%	-0.04	$799996	0.00%
LIXT	$7.21	-6.00%	-5.30	$89.11M	0.00%
NIVF	$1.05	-4.55%	0.04	$198988	0.00%

About Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals, Inc., a U.S.-based biopharmaceutical entity, is dedicated to developing therapeutic interventions for chronic hepatic ailments. Central to their efforts is Rencofilstat, a cyclophilin inhibitor that has successfully concluded Phase 2a clinical trials. This compound operates by disrupting multiple pathological pathways implicated in the worsening of liver disease. It is currently progressing through clinical development for non-alcoholic steatohepatitis (NASH) and is additionally being explored in nonclinical research for its potential to reduce liver fibrosis and lessen hepatocellular carcinoma tumor loads in experimental models of NASH. Moreover, Rencofilstat has exhibited antiviral properties against hepatitis B, C, and D viruses through diverse mechanisms. The company, established in 2013 and situated in Edison, New Jersey, rebranded as Hepion Pharmaceuticals, Inc. in July 2019, having previously operated as ContraVir Pharmaceuticals, Inc.

Hepion Pharmaceuticals, Inc. is headquartered in US.

Hepion Pharmaceuticals, Inc. (HEPA) stock trades at $0.05 with a market capitalization of $617116. The stock is valued at a price-to-earnings (P/E) ratio of -0.21, price-to-book of 0.33, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.03 and $0.11, and currently trades 54.5% below its 52-week high.

On profitability, Hepion Pharmaceuticals, Inc. generates a return on equity (ROE) of -102.45%, return on capital employed of -186.89%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.hepionpharma.com